For example, in the STEP 1 trial , patients taking semaglutide lost an average of 14.9% of their body weight over 68 weeks , compared with just 2.4% in the placebo group (NEJM study)
Pain 156 , 17551764 (2015)
Marques JG, Calado G, Martins P, Pinto PL
Glucagon-receptor agonism raises energy expenditure and mobilizes fat, which could in theory favor fat loss over muscle loss
What makes the evidence compelling for legal purposes is the consistency across multiple independent studies, the dose-response relationship (higher risk with longer use), and the fact that non-diabetic users taking the drugs solely for fat loss show the highest risk increase
Since they are so important to peptide secretions such as GLP1, one would think that a search would turn up evidence that probiotics are excellent weight support, as was indeed the case